$6.35
0.132.17%
Last update: Oct 2, 9:19 AM
$6.37
0.162.49%
Starling Oncology Inc
STLNNASDAQ
Starling Oncology (STLN) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Starling Oncology (STLN) last issued guidance on August 6, 2026 for fiscal year 2026. The company guided revenue in the range of $650M - $670M for the period.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.06 | $-0.08 | $-0.09 | $-0.12 |
| Actual | $-0.08 | $-0.02 | $-0.06 | $-0.14 |
| Surprise | -33.3% | +75.0% | +33.3% | -16.7% |
| Revenue | ||||
| Estimate | $156.9M | $142.6M | $140.3M | $122.5M |
| Actual | $161.3M | $147.4M | $142.0M | $136.6M |
| Surprise | +2.79% | +3.38% | +1.20% | +11.5% |
| Metric | Q3 '26E | Q4 '26E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $-0.05 | $-0.02 |
| Revenue | ||
| Consensus | $168.6M | $187.8M |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-0.08 | $-0.06 | -33.3 % |
| Q1 | May 7, 2026 | $-0.02 | $-0.08 | 75.0 % |
| Q4 | Mar 12, 2026 | $-0.06 | $-0.09 | 33.3 % |
| Q3 | Nov 13, 2025 | $-0.14 | $-0.12 | -16.7 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $161.28M | $156.91M | 2.79 % |
| Q1 | May 7, 2026 | $147.44M | $142.63M | 3.38 % |
| Q4 | Mar 12, 2026 | $141.96M | $140.27M | 1.20 % |
| Q3 | Nov 13, 2025 | $136.56M | $122.48M | 11.5 % |
